Chimeric antigen receptor T cell treatment in hematologic malignancies. Issue 1 (February 2016)

• Record Type: Journal Article
• Authors: Goker, Hakan; Malkan, Umit Yavuz; Demiroglu, Haluk; Buyukasik, Yahya
• Is Part Of: Transfusion and apheresis science. Volume 54:Issue 1(2016)
• Page Start: 35
• Page End: 40
• Publication Date: 2016-02
• Subjects: Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2016.01.011
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Adoptive transfer of T cells that have genetically engineered chimeric antigen receptors (CARs) is an encouraging treatment modality in the hematological malignancies. These T cells are capable of selectively recognizing tumor-associated antigens. There are a variety of reported, as well as ongoing studies on the utilization of CAR-T cells in the treatment of leukemia, myeloma, as well as B and T cell lymphomas. In this review, we aimed to highlight current understanding of this promising treatment modality, including its efficacy and adverse effects.